Original Article

Incidence and Clinical Predictors of Nonresponse to Hepatitis B Vaccination among Patients Receiving Hemodialysis: Importance of Obesity

Authors: Nimish Patel, PharmD, PhD, Magdalene M. Assimon, PharmD, Emily Bruni , Louise-Anne McNutt, PhD, Darius L. Mason, PharmD

Abstract

Objectives: The objectives of this study were to quantify the incidence of hepatitis B virus (HBV) vaccine nonresponse and identify clinical characteristics associated with vaccine nonresponse.

Methods: A retrospective cohort study was conducted among patients undergoing hemodialysis (HD) receiving the HBV vaccine. Study inclusion criteria were age 18 years and older, receipt of HD treatment for ≥1 month, receipt of ≥1 dose of HBV vaccine, availability of anti-HB surface antibody (anti-HBs) laboratory values ≥2 weeks after last HBV vaccine, and prevaccine anti-HBs value <10 mIU/mL. Clinical data were abstracted from patients’ medical records. The outcome of interest was vaccine nonresponse, defined as anti-HBs values <10 IU/mL. Multivariate regression was used to determine variables independently associated with vaccine nonresponse. Kaplan-Meier estimates were constructed for determining HBV vaccine response retention.

Results: Of the 119 patients evaluated, nonresponse was observed in 58%. Mean age at first vaccination for vaccine responders and nonresponders was 58.8 ± 16.5 and 65.9 ± 14.1 ( P = 0.01), respectively. Variables independently associated with nonresponse were age 58 years and older (adjusted relative risk, 95% confidence interval 1.62, 1.06–2.46; P = 0.02) and body mass index ≥36.4 kg/m 2 (adjusted relative risk, 95% confidence interval 1.66, 1.34–2.07; P < 0.01). Among the 50 patients who achieved an initial vaccine response, 26% were not able to maintain vaccine response upon subsequent anti-HBs measurement. The probability of retaining vaccine response over time was significantly modified by body mass index ≥25 kg/m 2 .

Conclusions: The frequency of nonresponse to the HBV vaccine was high among patients undergoing HD. The clinical covariates most predictive of vaccine nonresponse were advanced age at the time of vaccination and excess body weight.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bakke CK. Clinical and cost effectiveness of guidelines to prevent intravascular catheter-related infections in patients on hemodialysis. Nephrol Nurs J 2010;37:601-616.
 
2. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-999.
 
3. Tokars JI, Miller ER, Stein G. New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control 2002;30:288-295.
 
4. Laupland KB, Church DL, Mucenski M, et al. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003;187:1452-1459.
 
5. De Castro L, Araujo NM, Sabino RR, et al. Nosocomial spread of hepatitis B virus in two hemodialysis units, investigated by restriction fragment length polymorphism analysis. Eur J Clin Microbiol Infect Dis 2000;19:531-537.
 
6. US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
 
7. Lin SY, Liu JH, Wang SM, et al. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol 2012;13:97.
 
8. Velandia M, Fridkin SK, Cardenas V, et al. Transmission of HIV in dialysis centre. Lancet 1995;345:1417-1422.
 
9. Thompson ND, Novak RT, Datta D, et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. Infect Control Hosp Epidemiol 2009;30:900-903.
 
10. Ramalingam S, Leung T, Cairns H, et al. Transmission of hepatitis B virus (genotype E) in a haemodialysis unit. J Clin Virol 2007;40:105-109.
 
11. Al-Solaiman Y, Estrada E, Allon M. The spectrum of infections in catheter-dependenthemodialysis patients. Clin J Am Soc Nephrol 2011;6:2247-2252.
 
12. Szmuness W, Stevens CE, Zang EA, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981;1:377-385.
 
13. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362-366.
 
14. Dienstag JL, Werner BG, Polk BF, et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984;101:34-40.
 
15. Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984;311:496-501.
 
16. Buti M, Viladomiu L, Jardi R, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992;12:144-147.
 
17. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33.
 
18. Gilbert CL, Stek JE, Villa G, et al. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients. Vaccine 2014;32:6521-6526.
 
19. Alter MJ, Favero MS, Maynard JE. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 1986;153:1149-1151.
 
20. Edey M, Barraclough K, Johnson DW. Review article: hepatitis B and dialysis. Nephrology (Carlton) 2010;15:137-145.
 
21. Lanini S, Puro V, Lauria FN, et al. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med 2009;7:15.
 
22. Zhang H, Burthon S. Recursive Partitioning in the Health Sciences. New York: Springer, 1999.
 
23. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157:940-943.
 
24. Stevens CE, Toy PT, Taylor PE, et al. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992;90(1 Pt 2):170-173.
 
25. Chaves SS, Daniels D, Cooper BW, et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine 2011;29:9618-9623.
 
26. Okulicz JF, Mesner O, Ganesan A, et al. Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers. PLoS One 2014;9:e105591.
 
27. Elwell RJ, Neumann M, Bailie GR. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort study. Pharmacotherapy 2003;23:1558-1563.
 
28. Chow KM, Law MC, Leung CB, et al. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 2006;103:c89-c93v.
 
29. Ramezani A, Eslamifar A, Banifazl M, et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract 2009;63:394-397.
 
30. Kovacic V, Sain M, Vukman V. Efficient haemodialysis improves the response to hepatitis B virus vaccination. Intervirology 2002;45:172-176.
 
31. Grzegorzewska AE, Kaczmarek-Leki V, Mlot-Michalska M, et al. Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant 2011;26:970-976.
 
32. Grzegorzewska AE, Wobszal P, Jagodzinski PP. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res 2012;35:1-8.
 
33. Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
 
34. Ginaldi L, De Martinis M, D’Ostilio A, et al. The immune system in the elderly: I. Specific humoral immunity. Immunol Res 1999;20:101-108.
 
35. Burns EA, Lum LG, L’Hommedieu G, et al. Specific humoral immunity in the elderly: in vivo and in vitro response to vaccination. J Gerontol 1993;48:B231-B236.
 
36. Ginaldi L, De Martinis M, D’Ostilio A, et al. The immune system in the elderly: II. Specific cellular immunity. Immunol Res 1999;20:109-115.
 
37. Kooman JP, Usvyat L, van der Sande FM, et al. ‘‘Time and time again’’: oscillatory and longitudinal time patterns in dialysis patients. Kidney Blood Press Res 2012;35:534-548.
 
38. Cekmez F, Canpolat FE, Erdinc K, et al. Response to hepatitis B vaccine differs by birthweight among neonates. Vaccine 2011;29:3096-3097.
 
39. Simo Minana J, Gaztambide Ganuza M, Fernandez Millan P, et al. Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination. Vaccine 1996;14:103-106.
 
40. Halsey NA, Moulton LH, O’Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999;103(6 Pt 1):1243-1247.
 
41. Middleman AB, Kozinetz CA, Robertson LM, et al. The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis b immunization among adolescents. Pediatrics 2001;107:1065-1069.
 
42. Weber DJ, Rutala WA, Samsa GP, et al. Impaired immunogenicity of hepatitis B vaccine in obese persons. N Engl J Med 1986;314:1393.
 
43. Roome AJ,Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-2934.
 
44. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006;17:1453-1459.
 
45. Karlsson EA, Beck MA. The burden of obesity on infectious disease. Exp Biol Med (Maywood) 2010;235:1412-1424.
 
46. Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA 1997;277:1709-1711.
 
47. Cook IF, Williamson M, Pond D. Definition of needle length required for intramuscular deltoid injection in elderly adults: an ultrasonographic study. Vaccine 2006;24:937-940.
 
48. Wahl M, Hermodsson S. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response. Scand J Infect Dis 1987;19:617-621.
 
49. Ricks J, Molnar MZ, Kovesdy CP, et al. Racial and ethnic differences in the association of body mass index and survival in maintenance hemodialysis patients. Am J Kidney Dis 2011;58:574-582.
 
50. Launer LJ, Harris T. Weight, height and body mass index distributions in geographically and ethnically diverse samples of older persons. Ad Hoc Committee on the Statistics of Anthropometry and Aging. Age Ageing 1996;25:300-306.